Sermorelin (also known as sermorelin acetate or GHRH 1-29) is a synthetic 29-amino acid peptide analog of endogenous growth hormone-releasing hormone (GHRH). It acts as a GHRH receptor agonist, binding to receptors on the pituitary gland to stimulate the natural, pulsatile synthesis and release of the body’s own human growth hormone (hGH). This leads to increased circulating hGH and downstream insulin-like growth factor-1 (IGF-1) levels while preserving the normal regulatory feedback loops (including somatostatin inhibition).1
Key Research Description
In research and clinical contexts, sermorelin has been studied primarily for:
Diagnosis and treatment of growth hormone deficiency (GHD) in children (its original FDA-approved indications in 1990/1997 under brand names Geref).
Off-label or investigational use in adults for age-related decline in GH secretion (somatopause), body composition improvement, recovery, sleep quality, libido, and well-being.
Advantages highlighted in research (particularly compared to direct recombinant human growth hormone/rhGH injections):
Mimics natural pulsatile GH release rather than providing constant “square-wave” exposure.
Harder to overdose due to negative feedback regulation.
May help preserve or restore pituitary function and the broader neuroendocrine axis that declines with aging.
Potentially lower risk of certain side effects associated with supraphysiological exogenous GH/IGF-1 levels (e.g., less likelihood of sustained high IGF-1 driving certain metabolic or mitogenic concerns).1
Clinical studies (mostly small, older trials from the 1990s–2000s) have shown it can elevate IGF-1 to youthful levels in older adults, modestly increase lean body mass (e.g., ~1–3 lbs in some trials), improve certain mea5MGsures of strength or well-being, and support nitrogen balance, with mixed or limited effects on fat loss or bone density. Long-term robust data, especially for anti-aging or performance uses, remains limited.
